Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in Chinese Participants with ATTR-CM
NCT04814186Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Pfizer. Primary endpoints: Treatment-Emergent Adverse Events at 12 months and Treatment-Related Treatment-Emergent Adverse Events at 12 months. Started Jul 2021; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04814186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814186.